Method of detecting malignant neoplasms
OwnerGiovanni Giacomo Costainventor
Life of this patent
Estimating the term…
Abstract
A diagnostic test method of detecting malignant neoplasms is provided involving administering, to a subject under investigation, a labelled tracer compound capable of being metabolized by the subject. A sufficient period of time is allowed to elapse to permit the subject to metabolize the labelled tracer compound after which time the excretion products of the subject are analyzed for labelled products.
Claims18
A diagnostic test method for detecting malignant neoplasms employing as a tracer a radioactively labelled lipid selected from the group consisting of fatty acids, fat precursors, simple fats, phospholipids, steroids and sterols, the label being a stable or unstable isotope selected from the group consisting of carbon, hydrogen, oxygen and phosphorus wherein the metabolism of said lipid by subjects having malignant neoplasms is different than in subjects not having such neoplasms comprising:
- a. administering to a subject under controlled conditions a predetermined amount of a radioactively labelled lipid tracer, capable of being metabolized by the subject;
- b. waiting a sufficient time to allow for the metabolism of the labelled lipid tracer;
- and
- c. determining by radioactive measurements the amount of radioactive catabolites in the excretion products.
A diagnostic test method for detecting malignant neoplasms comprising:
- a. administering to a subject, under controlled conditions, an analytically significant amount of a labelled lipid tracer selected from the group consisting of fatty acids, fat precursors, simple fats, phospholipids, steroids and sterols, wherein the labelled tracer atom is selected from the group consisting of phosphorous-32, carbon-13, carbon-14, oxygen-18, deuterium, tritium;
- and
- b. waiting a sufficient time after administration to allow for the metabolism of the labelled tracer;
- and
- c. analyzing the excretion products of the subject for labelled compounds.
A diagnostic test method for detecting malignant neoplasms comprising:
- a. orally administering to a fasting subject, under controlled conditions, from about 3 to about 80 microcuries per subject of a carbon-14 labelled tripalmitin tracer;
- b. continuing said fasting by the subject for from about two to about six hours;
- c. waiting for an additional period of time such that the total period from the time of administration is from about 14 to about 18 hours to allow for the metabolism of the tripalmitin tracer;
- and
- d. analyzing the respiratory excretion products of the subject by slowly bubbling a quantitative amount of exhaled breath through an ethanol/methylcellosolve solution of known concentration until fully saturated with carbon dioxide, adding an appropriate amount of a scintillation solution, and recording the amount of carbon-14 labelled product in a liquid scintillation counter.
A diagnostic test method for detecting malignant neoplasms employing a radioactively labelled lipid wherein the metabolism of said lipid by subjects having malignant neoplasms is different than in subjects not having such neoplasms comprising:
- a. administering to a subject under controlled conditions, a predetermined amount of a radioactively labelled lipid tracer, capable of being metabolized by the subject;
- b. waiting a sufficient time to allow for the metabolism of the labelled lipid tracer;
- and
- c. determining by scintillation detection the amount of radioactive catabolites in the respiratory excretion products.
A diagnostic test method for detecting malignant neoplasms comprising:
- a. administering to a subject, under controlled conditions, an analytically significant amount of a labelled lipid tracer selected from the group consisting of fatty acids, fat precursors, simple fats, wherein the labelled tracer atom is selected from the group consisting of phosphorous-32, carbon-13, carbon-14, oxygen-18, deuterium, tritium;
- and
- b. waiting a sufficient time after administration to allow for the metabolism of the labelled tracer;
- and
- c. analyzing the respiratory excretion products of the subject for labelled compounds by scintillation detection.
Dependencies are inferred from the claim text.